Boosting Interleukin‐12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR‐Tagged Nanogold

The clinical use of interleukin‐12 (IL12), a cytokine endowed with potent immunotherapeutic anticancer activity, is limited by systemic toxicity. The hypothesis is addressed that gold nanoparticles tagged with a tumor‐homing peptide containing isoDGR, an αvβ3‐integrin binding motif, can be exploited...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Small (Weinheim an der Bergstrasse, Germany) Germany), 2019-11, Vol.15 (45), p.e1903462-n/a
Hauptverfasser:	Gasparri, Anna Maria, Sacchi, Angelina, Basso, Veronica, Cortesi, Filippo, Freschi, Massimo, Rrapaj, Eltjona, Bellone, Matteo, Casorati, Giulia, Dellabona, Paolo, Mondino, Anna, Corti, Angelo, Curnis, Flavio
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticancer properties Cytokines Depletion Equivalence Gold gold nanoparticles Homing Immune system immunotherapy Interleukins interleukin‐12 isoDGR motif Nanoparticles Nanospheres Nanotechnology Peptides Prostate Therapy Toxicity αvβ3 integrin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!